Life sciences company Avantor (NYSE:AVTR) will be announcing earnings results this Wednesday before the bell. Here’s what you need to know.
Avantor missed analysts’ revenue expectations by 1.4% last quarter, reporting revenues of $1.62 billion, down 5.3% year on year. It was a softer quarter for the company, with a slight miss of analysts’ revenue estimates and a miss of analysts’ organic revenue estimates.
Is Avantor a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Avantor’s revenue to decline 2.9% year on year to $1.64 billion, in line with the 2.1% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.22 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Avantor has missed Wall Street’s revenue estimates five times over the last two years.
Looking at Avantor’s peers in the research tools & consumables segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Bio-Techne posted flat year-on-year revenue, beating analysts’ expectations by 2%, and Revvity reported revenues up 5.8%, topping estimates by 1.1%. Bio-Techne traded up 1.9% following the results while Revvity was down 7%.
Read our full analysis of Bio-Techne’s results here and Revvity’s results here.
Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the research tools & consumables stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.6% on average over the last month. Avantor is down 7.8% during the same time and is heading into earnings with an average analyst price target of $13.04 (compared to the current share price of $11.25).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.